Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 303

1.

Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy.

Lammers WJ, Hirschfield GM, Corpechot C, Nevens F, Lindor KD, Janssen HL, Floreani A, Ponsioen CY, Mayo MJ, Invernizzi P, Battezzati PM, Parés A, Burroughs AK, Mason AL, Kowdley KV, Kumagi T, Harms MH, Trivedi PJ, Poupon R, Cheung A, Lleo A, Caballeria L, Hansen BE, van Buuren HR; Global PBC Study Group.

Gastroenterology. 2015 Aug 7. pii: S0016-5085(15)01094-X. doi: 10.1053/j.gastro.2015.07.061. [Epub ahead of print]

PMID:
26261009
2.

Data supporting updating estimates of the prevalence of chronic hepatitis B and C in the United States.

Gish RG, Cohen CA, Block JM, Brosgart CL, Block TM, Clary R, Le LT, Ninburg MH, Sandt L, Kowdley KV.

Hepatology. 2015 Aug 3. doi: 10.1002/hep.28026. [Epub ahead of print] No abstract available.

PMID:
26239816
3.

Comparison of first- and second-wave DAAs for HCV GT1: efficacy, safety, tolerability, and regimen complexity.

Burman BE, Kwo PY, Kowdley KV.

Hepatol Int. 2014 Jul;8(3):352-64. doi: 10.1007/s12072-014-9552-6. Epub 2014 Jul 9. No abstract available.

PMID:
26202638
4.

Update on hepatitis C: epidemiology, treatment and resistance to antiviral therapies.

Ness E, Kowdley KV.

Minerva Gastroenterol Dietol. 2015 Sep;61(3):145-58. Epub 2015 May 20.

PMID:
25990619
5.

Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials.

Alqahtani SA, Afdhal N, Zeuzem S, Gordon SC, Mangia A, Kwo P, Fried M, Yang JC, Ding X, Pang PS, McHutchison JG, Pound D, Reddy KR, Marcellin P, Kowdley KV, Sulkowski M.

Hepatology. 2015 Jul;62(1):25-30. doi: 10.1002/hep.27890. Epub 2015 Jun 1.

PMID:
25963890
6.

ACG Clinical Guideline: Primary Sclerosing Cholangitis.

Lindor KD, Kowdley KV, Harrison ME; American College of Gastroenterology.

Am J Gastroenterol. 2015 May;110(5):646-59; quiz 660. doi: 10.1038/ajg.2015.112. Epub 2015 Apr 14.

PMID:
25869391
7.

Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine.

Lalezari J, Sullivan JG, Varunok P, Galen E, Kowdley KV, Rustgi V, Aguilar H, Felizarta F, McGovern B, King M, Polepally AR, Cohen DE.

J Hepatol. 2015 Aug;63(2):364-9. doi: 10.1016/j.jhep.2015.03.029. Epub 2015 Apr 1.

8.

Glyceronephosphate O-acyltransferase as a hemochromatosis modifier gene: Another iron in the fire?

Handa P, Kowdley KV.

Hepatology. 2015 Aug;62(2):337-9. doi: 10.1002/hep.27813. Epub 2015 May 6. No abstract available.

PMID:
25820544
9.

ABT-450/ ritonavir and ABT-267 in combination with ABT-333 for the treatment of hepatitis C virus.

Minaei AA, Kowdley KV.

Expert Opin Pharmacother. 2015 Apr;16(6):929-37. doi: 10.1517/14656566.2015.1024653. Review.

PMID:
25800085
10.

Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir.

Younossi ZM, Stepanova M, Afdhal N, Kowdley KV, Zeuzem S, Henry L, Hunt SL, Marcellin P.

J Hepatol. 2015 Aug;63(2):337-45. doi: 10.1016/j.jhep.2015.03.014. Epub 2015 Mar 17.

PMID:
25795586
11.

A comprehensive assessment of environmental exposures among 1000 North American patients with primary sclerosing cholangitis, with and without inflammatory bowel disease.

Eaton JE, Juran BD, Atkinson EJ, Schlicht EM, Xie X, de Andrade M, Lammert CS, Luketic VA, Odin JA, Koteish AA, Kowdley KV, Chopra KB, Hirschfield GM, Chalasani NP, Lazaridis KN.

Aliment Pharmacol Ther. 2015 May;41(10):980-90. doi: 10.1111/apt.13154. Epub 2015 Mar 17.

12.

Improvement in liver histology is associated with reduction in dyslipidemia in children with nonalcoholic fatty liver disease.

Corey KE, Vuppalanchi R, Vos M, Kohli R, Molleston JP, Wilson L, Unalp-Arida A, Cummings OW, Lavine JE, Chalasani N; Nonalcoholic Steatohepatitis Clinical Research Network.

J Pediatr Gastroenterol Nutr. 2015 Mar;60(3):360-7. doi: 10.1097/MPG.0000000000000584.

PMID:
25714579
13.

Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1, -2, and -3 clinical trials.

Younossi ZM, Stepanova M, Marcellin P, Afdhal N, Kowdley KV, Zeuzem S, Hunt SL.

Hepatology. 2015 Jun;61(6):1798-808. doi: 10.1002/hep.27724. Epub 2015 Mar 18.

PMID:
25627448
14.

All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study.

Nelson DR, Cooper JN, Lalezari JP, Lawitz E, Pockros PJ, Gitlin N, Freilich BF, Younes ZH, Harlan W, Ghalib R, Oguchi G, Thuluvath PJ, Ortiz-Lasanta G, Rabinovitz M, Bernstein D, Bennett M, Hawkins T, Ravendhran N, Sheikh AM, Varunok P, Kowdley KV, Hennicken D, McPhee F, Rana K, Hughes EA; ALLY-3 Study Team.

Hepatology. 2015 Apr;61(4):1127-35. doi: 10.1002/hep.27726. Epub 2015 Mar 10.

15.

Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study.

Trivedi PJ, Lammers WJ, van Buuren HR, Parés A, Floreani A, Janssen HL, Invernizzi P, Battezzati PM, Ponsioen CY, Corpechot C, Poupon R, Mayo MJ, Burroughs AK, Nevens F, Mason AL, Kowdley KV, Lleo A, Caballeria L, Lindor KD, Hansen BE, Hirschfield GM; On behalf of the Global PBC Study Group.

Gut. 2015 Jan 7. pii: gutjnl-2014-308351. doi: 10.1136/gutjnl-2014-308351. [Epub ahead of print]

PMID:
25567117
16.

Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid.

Hirschfield GM, Mason A, Luketic V, Lindor K, Gordon SC, Mayo M, Kowdley KV, Vincent C, Bodhenheimer HC Jr, Parés A, Trauner M, Marschall HU, Adorini L, Sciacca C, Beecher-Jones T, Castelloe E, Böhm O, Shapiro D.

Gastroenterology. 2015 Apr;148(4):751-61.e8. doi: 10.1053/j.gastro.2014.12.005. Epub 2014 Dec 11.

17.

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.

Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, Chalasani N, Dasarathy S, Diehl AM, Hameed B, Kowdley KV, McCullough A, Terrault N, Clark JM, Tonascia J, Brunt EM, Kleiner DE, Doo E; NASH Clinical Research Network.

Lancet. 2015 Mar 14;385(9972):956-65. doi: 10.1016/S0140-6736(14)61933-4. Epub 2014 Nov 7. Erratum in: Lancet. 2015 Mar 14;385(9972):946.

PMID:
25468160
18.

NASH resolution is associated with improvements in HDL and triglyceride levels but not improvement in LDL or non-HDL-C levels.

Corey KE, Vuppalanchi R, Wilson LA, Cummings OW, Chalasani N; NASH CRN.

Aliment Pharmacol Ther. 2015 Feb;41(3):301-9. doi: 10.1111/apt.13035. Epub 2014 Nov 28.

19.

It TAK(es) 1 to prevent steatohepatitis and tumorigenesis.

Handa P, Kowdley KV.

Ann Hepatol. 2014 Nov-Dec;13(6):847-9. No abstract available.

20.

Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study.

Lammers WJ, van Buuren HR, Hirschfield GM, Janssen HL, Invernizzi P, Mason AL, Ponsioen CY, Floreani A, Corpechot C, Mayo MJ, Battezzati PM, Parés A, Nevens F, Burroughs AK, Kowdley KV, Trivedi PJ, Kumagi T, Cheung A, Lleo A, Imam MH, Boonstra K, Cazzagon N, Franceschet I, Poupon R, Caballeria L, Pieri G, Kanwar PS, Lindor KD, Hansen BE; Global PBC Study Group.

Gastroenterology. 2014 Dec;147(6):1338-49.e5; quiz e15. doi: 10.1053/j.gastro.2014.08.029. Epub 2014 Aug 23.

PMID:
25160979
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk